News and Conferences

Page 13 of 16

  1. 3rd Annual Neuroimmunology Drug Development Summit 2021 Virtual Conference – 27-29 April 2021

    The Neuroimmunology Drug Development Summit is the industry’s definitive and unrivalled forum focused on pushing the frontiers of targeting neuroinflammation for CNS Indications. Transpharmation is proud to be an Event Partner at this meeting and is joining the 80+ neuroimmunology drug development experts to present a poster on our new neuroinflammation models; Evaluation of Human ex vivo and Rodent in vivo Models of Inflammation for CNS Anti-Inflammatory Drug Development, as well as to learn from those pioneering the field, network and build meaningful future partnerships. To discover more about our Neuroimmunology & Neuroinflammation capabilities, please get in touch with us

    To view the work that we presented click here https://youtu.be/NDnTk6y6h3M

  2. BNA 2021 - British Neuroscience Association - Festival of Neuroscience 2021 Virtual Conference 12-15 April 2021

    Each year, the BNA Festivals aim to bring together multiple organisations from both academia and industry interested in brain research, creating a novel, multi-organisation forum featuring all areas of
    fundamental research in neuroscience and psychology. At the BNA 2021, Transpharmation is looking forward to being a part of the meeting, with our Cognition Lead and Scientific Liaison, John Huxter, presenting a workshop on improving translation between industry and academia in neuroscience under the topic of "Pitfalls and prospects for cognitive assays in preclinical research". Please feel free to visit us at our booth to discuss the specific translational models.
    For more information on the conference, please visit https://meetings.bna.org.uk/bna2021/programme_information/

  3. “Companies have no borders”, said Mark Duxon, CEO of Transpharmation

    Transpharmation’s CEO Mark Duxon was pleased to speak with Guy Martin of The Pharma Letter about the impact of #Brexit on CROs. We have opened our fourth lab, most recently in Poland, and now with a footprint in the UK and continental Europe we are able to extend our services and partnerships to mitigate against border pressures, optimising opportunities for innovation and exciting collaborations.Read the full interview here

  4. ADPD, 15th International Conference on Alzheimer's Disease and Parkinson's Disease – 9-14 March 2021

    Transpharmation’s Scientists Caoimhe Tyndall and Teresa Burke will be presenting posters on the topics of “Glial-neuronal interaction prompted by recombinant fibrillar protein constructs of alpha-synuclein – an invitro characterisation” & “A53T alpha-synuclein promotes a rapid neurodegeneration and motor deficit following AAV vector mediated expression in the rat substantia nigra” respectively.

  5. New Laboratory

    Transpharmation announces the opening of a new laboratory in Poland. “We see Poland rising within the biotechnology and drug-discovery sector, with pharmaceutical companies moving and expanding to develop new technologies and focus on novel treatments to tackle neurodegenerative, neuropsychiatric and neurodevelopmental diseases which affect us all,” reveals Mark Duxon CEO. This news comes not long after Transpharmation revealed the launch of additional laboratory space at Discovery Park, Kent, boosting its growing list of facilities and opening up further opportunities to expand its preclinical services.

    Read the full press release.

  6. InterVivo Solutions Issued Institutional Cannabis Research License By Health Canada

  7. ASENT - American Society of Experimental Neurotherapeutics 2021 Virtual Conference 22-25 of February 2021

    Transpharmation will be presenting posters on the topics of “Modulation of the p38 MAPK Pathway in Peripheral Blood Mononuclear Cells (PBMCs): Implications for screening novel anti-inflammatories in Alzheimer’s Disease (AD)” & “Establishment of a reversal learning assay in rats to investigate the effects of novel compounds on executive function.” To get more info on the topics of discussion and registration process please go to https://asent.org/

  8. Peer Review Journal Publication

    Frontiers in Psychiatry have just published a peer review journal by the Transpharmation Ireland team, led by Jack Prenderville. ‘The Antidepressant-Like Effects of a Clinically Relevant Dose of Ketamine Are Accompanied by Biphasic Alterations in Working Memory in the Wistar Kyoto Rat Model of Depression.’ Major depressive disorder, (MDD) is the leading cause of disability worldwide. The majority of antidepressant drugs require several weeks or months of treatment to demonstrate efficacy and a subset of patients are resistant to such interventions. In this publication we examine depressive-like behavioural phenotypes in the Wistar-Kyoto rat model of depression, establish and demonstrate an effective clinically relevant dose of the novel therapeutic agent ketamine. Please read the full publication

  9. Society for Neuroscience (SfN) digital event 11-13th January 2021

    Transpharmation's EEG experts Dr. John Huxter and Dr. Sandor Kantor discussed how EEG can bridge the gap between basic research, preclinical drug discovery and human clinical trials at a virtual social (SO39) at the SfN Connectome on Tuesday 12th January at 9-10am EST (2-3pm GMT). This social stimulated discussion around what EEG measures offer the best hope for predicting clinical outcomes, probing strengths, weaknesses, and usage of measures like ASSR and MMN.

  10. Neuronus 2020 IBRO neuroscience forum - 8th - 11th December 2020

    The scope of topics at this virtual conference, usually held in Kraków, Poland, will cover general neurobiology, cognitive and affective neuroscience, as well as clinical neurology. Ewa Sokolowska, Transpharmation’s Polish senior scientist will have her work on show, which goes beyond the standard study; Behavioural assessment of acute and a long-term antidepressant and anxiolytic efficacy in mice. For details of this study please contact us. To see our preclinical services in this therapeutic area please click here.

Page 13 of 16

Want to see our latest study results?

Sign up for our newsletter.

Emails with our latest study results and news, from time to time. Unsubscribe anytime. See our Privacy Policy.

Newsletters

  • What's Next in CNS Drug Discovery? Five Studies Worth Exploring
  • Advancing Science Through In Vivo Refinement and Innovation - Examples from Abuse Liability and Impulsivity Screening
  • Building Confidence in Decision Making
  • Welcome to Reading, UK
  • The Next Leap in Translational Neuroscience
  • Expanding Scientific Possibility
  • 2025 Was A Year of Momentum: Science, People and Partners
  • 2025 Was A Year of Momentum: Science, People and Partners
  • Seven Posters, One Goal: Driving Neuroscience Forward
  • Advancing Preclinical Science for Next-Gen Therapies
  • New Capabilities Coming Online
  • Discover What's New at Transpharmation
  • Unlock the Microbiome: Transform Health with Transpharmation's Advanced Studies
  • Experimental Autoimmune Encephalomyelitis (EAE): Maximising The Therapeutic Efficacy of Fingolimod
  • Cross-Species Epilepsy Research: Revealing the Potential of the Zebrafish Model
  • Monoamine depletion to induce chronic allodynia and behavioural changes: a model of fibromyalgia
  • Take your R&D pipeline into the AI era with Moseq (Motion Sequencing), our new behavioural machine-learning assay!
  • Canine Microbiome
  • Oral Health: Not just for Humans
  • Novel Object Recognition: A Reliable Assay for Addressing Cognitive Impairments in Schizophrenia
  • Pre-pulse Inhibition: A Promising Screening Tool for Novel Compounds
  • Natural and induced models of osteoarthritis in Beagle dogs
  • Utilizing Rapid Screening Tests to Assess the Antidepressant Potential of Psychedelic Analogues
  • Long-term antidepressant effect of ketamine and psilocybin in the Chronic Social Defeat stress model
  • Diabetes and Metabolic Syndrome
  • Transpharmation's Animal Health Services
  • Longevity Research Goes to the Dogs
  • Transpharmation's Cutting-Edge Antiepileptic Drug Screening: A Global Solution for Advancing Epilepsy Research
  • PTZ-treated Zebrafish provide a high throughput platform for screening novel anti-epileptic drugs
  • Beyond Seizures: Epilepsy Comorbidities Explored in Mouse Kindling Studies
  • Novelty-suppressed feeding and novelty-induced hypophagia: exploring sex differences and response to diazepam in C57BL/6J mice.
  • Development & validation of intrathecal dosing in rats and mice
  • Transpharmation's Mouse-EEG capability reveals cross-species effects of novel antidepressants ketamine and psilocybin
  • Oral Health: Not just for Humans...
  • Accelerate Your Diabetes Drug Development with Transpharmation's Dog Diabetes Models
  • Introducing our new data analysis service for tremor-plate signals!
  • Introducing the Scn1a mutant mouse model of Dravet Syndrome at Transpharmation
  • New validated pre-clinical model to assess treatments for post-surgical pain
  • Experimental Autoimmune Encephalomyelitis; Modelling Multiple Sclerosis and Beyond
  • New Preclinical Models of Migraine for Assessment of Rescue and Preventive Analgesic Treatments
  • Do Your Compounds Exhibit Anti-Inflammatory Compounds
  • Profile your anti-inflammatory compounds in primary human immune cells
  • New EEG services from Transpharmation. Read on for results...
  • Accelerate your Drug Discovery Research. Proven results, fast and cost effective
  • Urgent Treatments Needed for Parkinson's Disease
  • Poor bioavailability, is the liver or intestine to blame?
  • Laser Doppler; new validated protocols revealed.
  • Epilepsy models leading the way. Read on for results.
  • Profiling anti-inflammatory drugs; from rodent to human
  • The Mismatch Negativity Challenge
  • Accelerate your drug discovery research. Proven science based results cost-effectively.
  • Anxiety. Three preclinical tests; data revealed...
  • Seven new posters, presented at SfN, now available to view.
  • Name change announcement! News from the CEO.
  • Chronic fatigue: different etiologies influence translational models
  • Seven new translational studies to share with you at this year's SfN event. Read on for poster titles and contact details.
  • Translational value increased with non-evoked pain measures.
  • Rapid access to PK non-rodent studies. Leading expertise.
  • Essential tremor research
  • Can a psychedelic experience be modelled in rats?
  • Gender Differences in Pain. New research revealed!
  • New data on the effect of single dose psilocybin!
  • From ketamine to psychedelics, join our webinar starting tomorrow!
  • Long term delayed effects of psychedelics in preclinical models. Trailblazing results revealed!
  • Accreditation awarded with flying colours
  • Breaking news! Merger announcement between Transpharmation and InterVivo Solutions.
  • Take a look! New posters, nine therapeutic areas available to view now.
  • Nine new compelling studies to be revealed at SfN21!
  • Can changes in EEG improve neuropathic pain treatments?
  • 40Hz ASSR: sounds that change our thoughts about schizophrenia
  • Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin
  • Translational endpoints for preclinical pain - improving your chances.
  • Transpharmation aims for global standard. Let's talk about lab sustainability.
  • Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder.
  • Psilocybin: the power of mental reorganisation
  • Expansion to world class premises
  • Multiple therapeutic indications
  • Focus on pain
  • Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward.
  • Announcing Transpharmation Poland!